## Background: The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (
Ligand selectivity of cloned human and rat opioid mu receptors
β Scribed by Richard B. Rothman; Heng Xu; Jia Bei Wang; John S. Partilla; Hiroshi Kayakiri; Kenner C. Rice; George R. Uhl
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 513 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0887-4476
No coin nor oath required. For personal study only.
β¦ Synopsis
Opiate receptors play major roles in analgesic and euphoric effects of opiate drugs. Recent cloning of cDNAs encoding the rodent and human p receptor revealed high homology between the predicted receptors but also some sequence differences. To determine if these sequence differences produced significant changes in ligandselectivity profiles, we assessed these profiles in expressing COS and CHO cell lines using the agonist ligand [1251]IOXY-AG0 (6~-[12510do]-3,14-dihydroxy-17-methyl-4,5a-epoxymorphinan). This ligand's high specific activity (2,200 CUmmol) and high affinity for p opioid receptors generated high signal-to-noise ratio binding. The resulting ligandselectivity profiles of the human and rat p receptors reveal modest differences in affinities for morphine and naloxone in COS cells but not CHO cells. Ligand-selectivity profiles of the rat and human p receptors were otherwise similar. Interesting differences between these data and data previously obtained with the peptide agonist ['HI DAMGO suggest that the peptide and alkaloid agonists may label different domains of the p receptor. 0 1995 Wiley-Liss, Inc.* Opiate receptors, [1251]IOXY-AG0, ['HIDAMGO, CHO cells the Opioid agonist peptide' [3H1DAMG0 (Raynor et lgg4; Wang et lgg3' xu et 1995)' The Address rnnrint reouests to Richard B. Rothman. CPS. DIR. NlDA. 4940 East-
π SIMILAR VOLUMES
Previous data obtained with the cloned rat Β΅ opioid receptor demonstrated that the ''super-potent'' opiates, ohmefentanyl (RTI-4614-4) and its four enantiomers, differ in binding affinity, potency, efficacy, and intrinsic efficacy. Molecular modeling (Tang et al., 1996) of fentanyl derivatives bindi